Table 4 Comparison of oncologic outcomes with Western studies
Current study | Erstad et al. | Smith et al. | Stevenson et al. | ||
|---|---|---|---|---|---|
Period | 2000–2017 | 2001–2011 | 2004–2014 | 1996–2016 | |
Number of cohort (amputated) | 37 | 54 | 69 | 39 | |
Published | 2023 | 2018 | 2018 | 2017 | |
Amputation number and rate for localized STS | 3.4% (22/596) | (n = 54) | (n = 59) | (n = 39) | |
Amputation number and rate for primary localized STS | 1.8% (9/490) | (n = 18) | 4.1% (23/556) | (n = 16) | |
Localized STS | DSS | 89.9% | NA | 49.8%(3 year) | NA |
LRFS | 84.1% | NA | 89.6%(3 year) | NA | |
MFS | 84.6% | NA | 44.0%(3 year) | NA | |
Primary localized STS | DSS | 85.7% | 68% | 30.5%(OS, 3 year) | 52.2%(10 year) |
LRFS | 87.5% | 75% | 72.9%(3 year) | 90.0%(10 year) | |
MFS | 87.5% | 53% | 33.4%(3 year) | 31.0%(10 year) | |
Recurrent localized STS | DSS | 92.3% | 33% | 62.8%(OS, 3 year) | 44.1%(10 year) |
LRFS | 81.8% | 85% | 97.0%(3 year) | 83.7%(10 year) | |
MFS | 82.1% | 23% | 57.2%(3 year) | 42.2%(10 year) | |
Indications in primary localized STS* | a(22%), b(78%) | a(39%), b(61%) | b(13%) | b(50%), c(50%) | |
Indication and timing in recurrent localized STS* | a(23%), b(92%) | a(36%), b(41%) | b(16%) | a(17.4%), b(52.2%) | |